Serum ALCAM is a potential novel non-invasive marker for predicting the progression of IgA nephropathy
Zengyuan Luo, Linlin Zhang, Zaiyu Wang, Qi Xiong, Jieyu Tang, Yongwen Yang, Xueling Hu, Huipeng Ge, Xiangcheng Xiao, Rong Tang, Wei Lin · 2025
Read Serum ALCAM is a potential novel non-invasive marker for predicting the progression of IgA nephropathy by Zengyuan Luo, Linlin Zhang, Zaiyu Wang, Qi Xiong, Jieyu Tang, Yongwen Yang, Xueling Hu, Huipeng Ge, Xiangcheng Xiao, Rong Tang, Wei Lin (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12750689.txt.
Description
Zengyuan Luo, Linlin Zhang, Zaiyu Wang, and eight colleagues propose a blood marker for kidney disease progression in this two thousand twenty-five prospective study. ALCAM is a molecule that activates lymphocytes and guides them into tissues; its role in IgA nephropathy, a common kidney disease, was unknown. The authors enrolled seventy-one patients and forty-one controls, measuring ALCAM in blood and urine, and its expression in kidney tissue alongside its ligand S100B.
Circulating ALCAM ran higher in patients than controls and correlated with proteinuria and worse kidney pathology. Splitting patients at a cutoff of four point seven six nanograms per milliliter, the high group showed more severe clinical and pathological features. Statistical modeling identified high serum ALCAM as an independent risk factor for progression, and that group had lower cumulative kidney survival. The authors offer serum ALCAM as a non-invasive prognostic marker.
Catalog record
| CREATOR | Zengyuan Luo, Linlin Zhang, Zaiyu Wang, Qi Xiong, Jieyu Tang, Yongwen Yang, Xueling Hu, Huipeng Ge, Xiangcheng Xiao, Rong Tang, Wei Lin |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 43 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |